At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
Tafasitamab +1 moredrug
Likely dose
Tafasitamab 12 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
In Brief
A Phase 2 clinical trial evaluating Tafasitamab and Lenalidomide for Diffuse Large B-cell Lymphoma. Completed, enrolled 81 participants across 57 sites in 10 countries.
Detailed Summary
This is a Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma
CountriesBelgium, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartMar 2016
Primary CompletionNov 2022
Study CompletionApr 2023
TodayJul 2026
First PostedMar 26, 2015
Enrollment StartMar 29, 2016
Primary CompletionNov 14, 2022
Study CompletionApr 19, 2023
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 11.3 years ago
Interventions
Tafasitamabdrug
12 mg/kg
Lenalidomidedrug
25 mg